<p>Characterization of the anti-E protein antibody response in plasma of subclinical and hospitalized post-primary DENV infected patients.</p>

Created in Biorender. <b>B.</b> Mean Fluorescence Intensity (MFI) of IgG binding to EDIII derived from DENV1-4 and ZIKV of plasma samples of subclinical (S: n = 6; numbered S1 to S6) and hospitalized (H; n = 9; numbered H1 to H9; either uncomplicated dengue (D), n = 4 or dengue with warning signs (DWWS), n = 5) individuals infected with DENV1 (left) or DENV2 (right) at day of inclusion <b>C.</b> Heatmap representation of MFI of IgG binding to EDIII derived from DENV1-4 and ZIKV.

Each row represents one individual. <b>D.</b> Mean Fluorescence Intensity of IgG binding to DENV1 sE-dimer (green) or sE (orange), or DENV2 sE-dimer (blue) or sE (brown) in day 5 plasma samples of subclinical (S: n = 4) and hospitalized (H; n = 9) individuals infected with DENV1 (left) or DENV2 (right). (B-C) IgG binding was measured by using a multiplex microsphere immunoassay (MIA) and are represented as median fluorescence intensity (MFI). <b>E.</b> Neutralizing antibody titers against DENV1 and DENV2 were compared between subclinical cases (blue; n = 5) and hospitalized patients (red; n = 9) on D5 plasma and the data shown as focus reduction neutralization test 50 (FRNT50).